

Pharmacotherapy of Bronchial Asthma

Dr. Shaymaa F. Abbas Department of Pharmacology 2018

Objectives

- This subject will be covered in two lectures
- The principal drugs used in asthma
- Classification of these drugs according to mechanism of action
- The quick-relief drugs of asthma
- Drugs used in prophylaxis of asthma



What is bronchial asthma?

Bronchial asthma is a chronic <u>inflammatory</u> airways disease, that is characterized by <u>hyper-responsiveness</u> of the airways to certain stimuli, and resulted in recurrent reversible attacks of <u>bronchoconstriction</u>

Pathophysiology







Classification according to mechanism of action

1. Drugs that decrease airways inflammation and hyper-responsiveness (Anti-inflammatory drugs): **Corticosteroids** Leukotrienes pathway modifiers Mast cell stabilizers 2. Bronchodilators: β₂ agonists **Xanthine derivatives** Anticholinergics

Anti inflammatory drugs



Glucocorticoids



Mechanism of action in asthma

1-Inhibit the inflammatory response to Ab-Ag reaction:

Inhibit influx of inflammatory cells Inhibit synthesis of inflammatory mediators & chemokines Inhibit release of inflammatory mediators Decrease mucosal edema



 Decrease bronchial mucous secretion
 Increase number & sensitivity of endogenous β2-receptors

Types of glucocorticoids

1. Inhalational steroids: use in chronic asthma

e.g. Fluticasone, Budesonide, Beclomethasone

- These drugs are highly lipid soluble with extensive 1st pass metabolism, so if systemic absorption occur, systemic side effects are less likely to occur
- Initial response noticed after 6-8 hr., with maximum response 1-2 weeks later





nebulizer





Side effects:

- 1- Oropharyngeal candidiasis
- 2- Dysphonia

Using of spacer and mouth rinsing decrease local side effects

3- Systemic side effects especially, in children and with high doses





<u>2- Oral :</u>

Drugs: prednisone or prednisolone

• Typically: can be used for 5 days with no need for tapering

Indications:

• As maintenance therapy in acute severe asthma and status asthmaticus



3- Intravenous

- e.g. Methylprednisolone, hydrocortisone, dexamethasone
- IV route used in acute severe asthma (failure of bronchodilators) and status asthmaticus

Leukotrienes pathway modifiers

• Leukotrienes receptor antagonists Montelukast, Zafirlukast

• Leukotriene synthesis inhibitors Zileuton

Leukotrienes receptors antagonists

• Montelukast, Zafirlukast

Both are having similar action and clinical uses

Mechanism of action

Competitively block the common cysteinyl – Leukotrienes (C4, D4 and E4) receptors in respiratory tract so preventing their bronchoconstriction effect

• They are given orally



Clinical uses

- 1. Alternative for inhaled glucocorticoid as prophylactic therapy for mild, moderate asthma
- 2. Prevention of aspirin induced asthma
- Not used for terminating of acute asthma (they prevent bronchoconstriction rather than dilate the already constricted bronchi)

Side effects

• headache, rashes, muscle pain, eosinophilia.

Zileuton is the only commercially available inhibitor of the 5-Lipoxygenase pathway

Clinical uses

Management of chronic, persistent asthma

Side effects

Headache (10%), elevated liver enzymes

Mast cell stabilizers

- Na-chromoglycate and Nedocromil-Na
- Reduce hyper-reactivity of the bronchial tree, prevent further attacks
- Prevent eosinophilic and neutrophilic chemotaxis
- Stabilize the mast cell of the bronchial airway
- Reduce the irritation of airway nerve endings

20/46

- There **is no bronchodilator effect**
- They are given by inhalation in asthma



Clinical uses

- 1. Prophylaxis in allergic and exercise-induced bronchial asthma.
- 2. Allergic rhinitis
- 3. Allergic conjunctivitis

Side effects: cough, throat irritation.





- Hi blocker (antihistamine) and mast cell stabilizer
- prevent degranulation of mast cells and release of inflammatory mediators in response to stimuli.
- It is **not a bronchodilator**.
- <u>Use</u>: long-term prophylaxis of allergic asthma

Bronchodilators



Selective β2 agonists Xanthine derivatives

3. Anticholinergics



B₂ agonists

- **1. Short-acting β2 adrenergic receptor agonists** (Salbutamol, terbutaline)
- **2. Long-acting β2 adrenergic receptor agonists** (Salmeterol; formoterol)

Selective B2 Agonists

Mechanisms of Action



- 1) Stimulate B2 receptors of bronchial smooth
- muscle--Stimulation of Adenylate cyclase---Increase intracellular cAMP----Smooth muscle relaxation \rightarrow Bronchodilatation
- 2) Act on the β 2 receptor of the mast cells--increase c-AMP production \rightarrow Stabilization of the mast cell membrane \rightarrow No inflammatory mediators release \rightarrow No bronchoconstriction





Salbutamol

- Can be administered orally, i.v. or by inhalation
- Bronchodilatation is immediate when given by inhalation
- Inhaled salbutamol is the drug of choice for acute bronchial asthma and for rapid prophylaxis against exercise-induced asthma
- Duration of action is short (4 hours)



It is used only on need because continuous use leads to down- regulation of bronchial β2 receptors results in tolerance (tachyphylaxis).

Salmeterol



- Only administered by **inhalation**.
- It is **not** effective in acute attack because it has a slow onset of action (20 minutes).
- It has as a **long duration of 12 hours** because it is a highly lipid soluble as it contains a lipophilic side chain. This permits it to dissolve in the smooth muscle cell membrane adjacent to B2 receptor, then released slowly to act on receptors



- Salmeterol is used for: <u>long term prophylaxis</u> <u>of bronchial asthma</u>
- Since corticosteroids increase sensitivity of
- β 2 receptors to β 2 agonists, they may be given together
- Tolerance for salmeterol does not occur



- ✓ Tachycardia and tachyarrhythmia (due to stimulation of cardiac B1 receptors)
- ✓ Hypokalaemia, hyperglycemia and tremor due to stimulation of B2 receptors



25 year old asthmatic patient is complaining of severe shortness of breath and wheeze What is the drug of choice?

Inhaled antimuscarinic bronchodilators

ex. lpratropium, oxitropium, tiotropium

- Anticholinergics cause bronchodilatation
- by blocking muscarinic receptors
- Cannot be given orally, only by inhalation
 (achieve high concentrations in the bronchial air way.

32/46

 Less systemic effect because they are permanently charged so poorly absorbed
 after inhalation from lungs or GIT.



Clinical uses

1) Adjuvant to ß2 receptor agonists in acute asthma and status ashmaticus

2) Chronic obstructive pulmonary diseases (COPD)



Theophylline, Aminophylline

Mechanisms of Action

Inhibit phosphodiasterase enzyme PD4 that degrade c-AMP, c- AMP accumulate in the bronchial smooth muscle and causes bronchodilatation.

Increase c-AMP production \rightarrow Stabilization of the mast cell membrane \rightarrow No inflammatory mediators release \rightarrow No bronchoconstriction

34/46





3-Block adenosine receptor, prevents adenosine to cause contraction of the bronchial smooth muscle.

Pharmacological effects:



- ✓ Lung—bronchodilation
- \checkmark CNS— stimulation, excitement, convulsions.
- ✓ CVS -positive ionotropic and chronotropic
 effects
- In high level—toxicity— fatal cardiac arrhythmia
- ✓ Kidney— diuretic action, decrease
- Na reabsorption in proximal tubules
 ✓ GIT—f gastric acid and pepsin secretion , vomiting



- Theophylline is the prototype, it is water insoluble
- Given orally for chronic asthma, COPD
- > Aminophyiline
- Water soluble salt prepared by mixing theophylline with Ethylene di-amine.
- Given intravenously in acute asthma and status asthmaticus.



Total i.v. loading dose should be given slowly (**at least in 20minutes**) **to avoid CNS and CVS side effects**, resulted from exposure of heart and brain to high concentrations before drug distribution is complete

The loading dose **should be avoided** in any patient who is already taking, methyl xanthine preparation i.e. Oral theophylline or enzyme inhibitor drugs (always enquire about this before injecting) 40/46

Why theophylline require serum level monitoring TDM



- 1) Wide spreads pharmacological action
- 2) Low therapeutic index
- Therapeutic blood level is 5-15mg/L.
- The CNS and CVS side effects may occur in >20mg/L
- 3) Marked inter-individual variation in rate of
- metabolism ie . It is slowly in **elderly > 60 years**,
- premature infant, obese, patients with heart failure and those with liver cirrhosis 41/46



4) enzyme saturable at therapeutic doses, metabolism follows zero order kinetic.
4) Dose need to be reduced with enzyme inhibitors as erythromycin. ciprofloxacin, allopurinol and contraceptive pills.

Side effects



- 1. CNS: tremor, anxiety, insomnia, restlessness, convulsions
- 2. CVS: hypotension, ventricular arrhythmias, ventricular fibrillation, cardiac arrest and death
- **3. GIT:** nausea and vomiting
- 4. Metabolic: hypokalaemia

RECAS

Advantages of inhalation route in general:

- Achieve maximum local concentration and response, so lower doses are needed
- Less systemic absorption so less systemic side effects

Types of inhalation devices:

- Metered dose inhaler, dry powder or aerosoles
- Nebulizer



Improper use of inhaler can result in a large fraction (approximately 80-90 %) of inhaled drug to be deposited in the oropharynx rather than bronchial smooth muscle or swallowed, excreted and/or resulted in systemic or local side effects.



To avoid this

1) The patient should be instructed to coordinate activation of the inhaler with deep, slow inspiration and then hold breath for few minutes. 2) Spacer (chamber interposed between the inhaler and patient mouth) to act as an aerosol reservoir that improve drug delivery to airways and reduce impaction of drug particles in oropharynx and improve inhaled to swallowed drug ratio $_{46/46}$

Quick-relief medications

- REAL PROPERTY OF THE PROPERTY
- ✓ Inhaled short-acting β_2 -agonists (SABAs)
- ✓ Anticholinergics
- ✓ Systemic corticosteroids
- ✓ Intravenous aminophylline
 - for refractory cases

✓ Magnesium sulfate

